Results 121 to 130 of about 14,491 (226)

Abstracts

Cancer Science, Volume 117, Issue S1, Page 1-2148, January 2026.
wiley   +1 more source

Oral absorption from surfactant-based drug formulations:the impact of molecularly dissolved drug on bioavailability [PDF]

Enabling drug formulations are often required to ensure sufficient absorption after oral administration of poorly soluble drugs. While these formulations typically increase the apparent solubility of the drug, it is widely acknowledged that only ...
Bauer-Brandl, Annette, Brandl, Martin, Holzem, Florentin Lukas, Parrott, Neil, Schaffland, Jeannine Petrig, Stillhart, Cordula   +5 more
core   +1 more source

Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study

Oncology Letters
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have transformed the treatment paradigm for patients with ALK-positive non-small cell lung cancer (NSCLC).
Qing Liu, Ying Fu, Jun Guo, Chunqiu Fu, N. Tang, Chufeng Zhang, Xiao Han, Zhehai Wang   +7 more
semanticscholar   +1 more source

A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a STRN-ALK fusion by artificial intelligence and molecular modelling: a case report

Translational Lung Cancer Research
Background Non-small cell lung cancers (NSCLCs) with ALK fusions are effectively treated with ALK tyrosine kinase inhibitors (TKIs). The widespread use of next-generation sequencing (NGS) assays to study the molecular profile of NSCLCs, can identify rare
Massimo Barberis, A. Rappa, F. de Marinis, Giuseppe Pelosi, E. Guerini Rocco, Yinxiu Zhan, Guido Tiana   +6 more
semanticscholar   +1 more source

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature

Lung Cancer: Targets and Therapy, 2018
Lei Deng,1 Janaki Sharma,2 Elizabeth Ravera,2 Balazs Halmos,2 Haiying Cheng2 1Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA; 2Department of Oncology, Montefiore Medical Center/Albert Einstein College of
Deng L, Sharma J, Ravera E, Halmos B, Cheng H   +4 more
doaj  

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports

Frontiers in Oncology
IntroductionAberrant expression of anaplastic lymphoma kinase (ALK) is found in 3%–7% of patients with non-small cell lung cancer (NSCLC). Alectinib is a tyrosine kinase inhibitor used as first-line treatment targeting ALK-positive tumors.
Paul Wheatley-Price, Boaz Wong, Hely Shah, Harman Sekhon, Sara Moore   +4 more
doaj   +1 more source

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. [PDF]

, 2017
Jalal, Shadia I., Mamdani, Hirva
core   +1 more source

Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.

The Journal of the National Comprehensive Cancer Network
More than 90 distinct fusion partners of ALK rearrangement have been identified. Different ALK fusions may exhibit different sensitivities to ALK tyrosine kinase inhibitors. The emergence of rare fusions poses significant challenges to targeted therapies.
Quanying Tang, Tong Li, F. Ren, Xuanguang Li, Weibo Cao, Haochuan Yu, Fuling Mao, Cancan Cao, L. Zu, Song Xu   +9 more
semanticscholar   +1 more source

Epithelioid inflammatory myofibroblastic sarcoma treated with Alectinib: a case report and literature review

Frontiers in Oncology
Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an extremely rare and aggressive form of inflammatory myofibroblastic tumor. Clinically, it has a high risk of relapse and peripheral organ infiltration, and it responds poorly to conventional ...
Xinchun Wu, Junxi Zhu, Yichao Yan, Dongfeng Niu, Lin Chen, Ning Ning, Yankai Zhang   +6 more
semanticscholar   +1 more source

Emerging resistance pathways in lung cancer: what has ROS-1 taught us? [PDF]

, 2018
Alrifai, D, Forster, MD, Janes, SM
core   +1 more source